Showing results (171-180 of 1,899) with videos related to
Sort By:
Pageof 190
Neuro-Oncology Practice|November 15, 2021
BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trialsYing Yuan, Jing Wu, Mark R GilbertDiscover Oncology|March 21, 2024
FAM83D acts as an oncogene by regulating cell cycle progression via multiple pathways in synovial sarcoma: a potential novel downstream target oncogene of anlotinibZi-Mei Liu, Ying Yuan, Lei JinBiometrics|February 16, 2024
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparisonYong Zang, Peter F Thall, Ying YuanJournal of Controlled Release : Official Journal of the Controlled Release Society|April 7, 2025
Photothermal treatment of prostate tumor with micellar indocyanine green and napabucasin to co-ablate cancer cells and cancer stem cellsYanyi Qu, Beibei Guo, Songsong Zhao, et al.Organic Letters|October 18, 2014
Diastereo- and enantioselective propargylation of benzofuranones catalyzed by pybox-copper complexLong Zhao, Guanxin Huang, Beibei Guo, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|April 24, 2025
Polymersome-enabled brain codelivery of STAT3 siRNA and CpG oligonucleotide boosts chemo-immunotherapy of malignant gliomaSongsong Zhao, Zhiwei Sun, Mingyu Xia, et al.International Journal of Environmental Research and Public Health|March 29, 2023
Heterogeneous Electro-Fenton-Catalyzed Degradation of Rhodamine B by Nano-Calcined PyriteYu Tan, Changsheng Zhao, Qingfeng Chen, et al.Biometrics|July 6, 2019
An adaptive trial design to optimize dose-schedule regimes with delayed outcomesRuitao Lin, Peter F Thall, Ying YuanStatistics in Medicine|October 18, 2019
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapiesYanhong Zhou, J Jack Lee, Ying YuanJournal of the National Cancer Institute|March 30, 2019
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer ImmunotherapyRuitao Lin, Robert L Coleman, Ying YuanPageof 190